Urinary pH Is Highly Associated With Tumor Recurrence During Intravesical Mitomycin C Therapy for Nonmuscle Invasive Bladder Tumor
Authors:
- 31 March 2011
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 185 (3) , 802-806
Abstract
In recent years some reports have suggested without any significant evidence that mitomycin C instillation would be more effective with urinary alkalinization. We investigated the association between urinary pH and the efficiency of mitomycin C instillation.We identified 130 patients treated with transurethral resection of a bladder tumor and adjuvant intravesical mitomycin C instillation between 1985 and 2008 at Keio University Hospital. Urinary pH was determined in 124 of the 130 patients just before mitomycin C administration during the scheduled instillation period. These 124 patients were assigned to groups according to urinary pH in increments of 0.5 and the association between urinary pH and clinicopathological characteristics was evaluated.Mean±SD urinary pH was 5.77±0.05 (range 5.00 to 7.66) during the scheduled instillation period. Urinary pH was 5.00 to 5.49, 5.50 to 5.99, 6.00 to 6.49, 6.50 to 6.99 and 7.00 in 39, 46, 25, 7 and 7 patients, respectively. Patients were further divided into 2 groups by urinary pH using a cutoff of 5.5, including 39 with pH less than 5.5 and 85 with pH 5.5 or more. Age, gender, tumor grade, primary/recurrent disease, pathological stage and the presence or absence of concomitant carcinoma in situ were not significantly difference between the 2 groups. Multivariate analysis revealed that categorical urinary pH was an independent risk factor for tumor recurrence (HR 1.75, p=0.032). Three and 5-year recurrence-free rates were 64.2% and 52.9% in patients with pH 5.5 or greater, and 41.9% and 38.4% in those with pH less than 5.5, respectively (p=0.046). Multivariate analysis showed that the HR of urinary pH for tumor recurrence was 1.84 and 2.54 at the 5.4 and 5.2 cutoffs, respectively.Results suggest that urinary pH more than 5.5 is associated with a decreased risk of tumor recurrence in patients treated with intravesical mitomycin C for nonmuscle invasive bladder cancer. Monitoring urinary pH during mitomycin C adjuvant treatment and modifying pH for urine alkalization may improve the therapeutic efficacy of mitomycin C instillation.Keywords
This publication has 20 references indexed in Scilit:
- Surveillance of urothelial carcinomaCancer, 2009
- Intravesical Treatments of Bladder Cancer: ReviewPharmaceutical Research, 2008
- Phase II Marker Lesion Study With Intravesical Instillation of Apaziquone for Superficial Bladder Cancer: Toxicity and Marker ResponseJournal of Urology, 2006
- The Effect of Ofloxacin on Bacillus Calmette-Guerin Induced Toxicity in Patients With Superficial Bladder Cancer: Results of a Randomized, Prospective, Double-Blind, Placebo Controlled, Multicenter StudyJournal of Urology, 2006
- Complications of Intravesical Therapy for Urothelial Cancer of the BladderJournal of Urology, 2006
- Multicentric Study Comparing Intravesical Chemotherapy Alone and With Local Microwave Hyperthermia for Prophylaxis of Recurrence of Superficial Transitional Cell CarcinomaJournal of Clinical Oncology, 2003
- Intravesical Electromotive Mitomycin C Versus Passive Transport Mitomycin C for High Risk Superficial Bladder Cancer: A Prospective Randomized StudyJournal of Urology, 2003
- Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer2003
- 5-YEAR FOLLOWUP OF A RANDOMIZED PROSPECTIVE STUDY COMPARING MITOMYCIN C AND BACILLUS CALMETTE-GUERIN IN PATIENTS WITH SUPERFICIAL BLADDER CARCINOMAJournal of Urology, 1999
- A Randomized Multicenter Trial of Adjuvant Therapy in Superficial Bladder Cancer: Transurethral Resection Only Versus Transurethral Resection Plus Mitomycin C Versus Transurethral Resection Plus Bacillus Calmette-GuerinJournal of Urology, 1996